Clinical trial
An Open Label, Phase I Trial to Investigate the Pharmacokinetics and Pharmacodynamics of Linagliptin (BI 1356) 5 mg After Single and Multiple Oral Administration in Patients With Type 2 Diabetes Mellitus of African American Origin for 7 Days
NCT00935220 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label, Phase I Trial to Investigate the Pharmacokinetics and Pharmacodynamics of Linagliptin (BI 1356) 5 mg After Single and Multiple Oral Administration in Patients With Type 2 Diabetes Mellitus of African American Origin for 7 Days
- Lead sponsor
- Boehringer Ingelheim
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- June 30, 2009
- Completion date
- Not reported
- Enrollment
- 41 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.